Jubilant Pharmova board to consider raising funds via NCDs on Oct 12

1 min read | Published on 07 Oct 2026, 08:55 PM |Updated on 07 Oct 2026, 08:55 PM

Reviewed by

Naman SScanX News Team

Add as a preferred
source on Google

Key Highlights

Board meeting scheduled for October 12, 2026
Agenda includes raising funds via Non-Convertible Debentures
Shareholders' approval may be sought for the issuance
Filing made under SEBI LODR Regulation 29

*this image is generated using AI for illustrative purposes only.

Jubilant Pharmova Limited has scheduled a Board of Directors meeting for Monday, October 12, 2026. The primary agenda is to consider and approve the raising of funds through the issuance of Non-Convertible Debentures (NCDs) or other permitted securities.

The company filed this intimation with BSE Limited and National Stock Exchange of India Limited on October 7, 2026. The filing was made pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Meeting Agenda Details

The Board will evaluate the proposal to issue NCDs and/or such other securities as may be permitted under applicable laws. Additionally, the directors will approve seeking shareholders' approval if required for this capital raising initiative.

Item	Detail
Company	Jubilant Pharmova Limited
Meeting Date	October 12, 2026
Primary Agenda	Fundraising via NCDs/securities
Regulatory Ref	SEBI LODR Reg 29

Disclosure Compliance

The company confirmed that this information is also available on its official website. The notice was signed by Naresh Kapoor, Company Secretary, digitally on October 7, 2026. This procedural step ensures transparency regarding potential changes in the company's debt structure and capital base.

Historical Stock Returns for Jubilant Pharmova

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.48%	-7.02%	+5.42%	+14.09%	-11.13%	+55.90%

How will the proceeds from the NCD issuance be allocated between debt refinancing and capital expenditure for new pharmaceutical projects?

What is the expected impact of this additional debt on Jubilant Pharmova's credit rating and cost of borrowing in the current interest rate environment?

Will the proposed securities issuance dilute existing equity holders' stakes, or is it strictly limited to non-convertible instruments?

Jubilant Pharmova

View Company Insights

View All News

Jubilant Pharmova receives ₹87.31 crore GST show cause notice from Mysore

0 min read | Published on 01 Sept 2026, 12:51 PM |Updated on 01 Sept 2026, 01:11 PM

Reviewed by

Jubin VScanX News Team

Add as a preferred
source on Google

Key Highlights

Jubilant Pharmova received a ₹87.31 crore GST show cause notice from Mysore authorities
The demand covers FY23 and includes ₹33.58 crore in tax, interest, and penalty
Allegations involve ineligible ITC and discrepancies in e-waybill records
Company contests the notice as legally incorrect and expects no financial impact

*this image is generated using AI for illustrative purposes only.

Jubilant Pharmova has received a show cause notice proposing a GST demand of ₹87.31 crore from the Assistant Commissioner of Commercial Taxes (Enforcement)-4, Mysore, for FY23.

Notice details

The notice, dated August 31, 2026, cites issues including alleged ineligible input tax credit (ITC), excess ITC availed, and differential tax liability based on e-waybill records.

The following table summarises the breakdown of the proposed demand:

Component	Amount
GST (Tax)	₹33.58 crore
Interest	₹20.15 crore
Penalty	₹33.58 crore
Total	₹87.31 crore

Company response

Jubilant Pharmova stated that the notice is factually and legally incorrect and was issued without proper verification or opportunity to respond. The company claims to have a strong case in its favour and expects no financial or operational impact.

It is currently preparing a detailed reply with documentary evidence to contest the demand before the Mysore tax authorities.

Historical Stock Returns for Jubilant Pharmova